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Abstract
 
Familial hypertrophic cardiomyopathy is a disease gener-
ally believed to be caused by mutations in sarcomeric pro-
teins. In a family with hypertrophic cardiomyopathy linked
to polymorphic markers on chromosome 11, we found a
new mutation of a splice donor site of the cardiac myosin-
binding protein-C gene. This mutation causes the skipping
of the associated exon in mRNA from lymphocytes and myo-
cardium. Skipping of the exon with a consecutive reading
frame shift leads to premature termination of translation
and is thus expected to produce a truncated cardiac myosin-
binding protein-C with loss of the myosin- and titin-bind-
ing COOH terminus. However, Western blot analysis of
endomyocardial biopsies from histologically affected left
ventricular myocardium failed to show the expected trun-
cated protein.
These data show for the first time that a splice donor site
mutation in the myosin-binding protein-C gene is tran-
scribed to cardiac mRNA. Truncated cardiac myosin-bind-
ing protein-C does not act as a “poison polypeptide,” since
it seems not to be incorporated into the sarcomere in signifi-
cant amounts. The absence of mutant protein and of signifi-
cantly reduced amounts of wild-type protein in the presence
of the mutated mRNA argues against the “poison protein”
and the “null allele” hypotheses and suggests yet unknown
mechanisms relevant to the genesis of chromosome-11–
associated familial hypertrophic cardiomyopathy. (
 
J. Clin.
Invest
 
. 1997. 100:475–482.) Key words: cardiac myosin-
binding protein-C 
 
•
 
 myocardial tissue 
 
•
 
 null allele 
 
•
 
 sarco-
mere assembly 
 
•
 
 cotranslation
 
Introduction
 
Familial hypertrophic cardiomyopathy (FHC)
 
1
 
 is inherited as
an autosomal dominant disease that is characterized by unex-
plained cardiac hypertrophy (1). Previous genetic analyses
have shown positive linkage to five different loci and four dis-
ease genes have been identified: 
 
b
 
-myosin heavy-chain (2, 3),
 
a
 
-tropomyosin (4, 5), cardiac troponin T (5, 6), and, recently,
cardiac myosin-binding protein-C (MyBP-C) on chromosome
11p13-q13 (7–9). The disease gene for the chromosome-7 asso-
ciated form of FHC is still unknown (10). Based on altered
lymphocyte cDNA, the thus far described mutations of MyBP-C
are predicted to produce a truncated cardiac protein with dis-
ruption of the titin and myosin-binding COOH-terminal re-
gion. At present, it is unknown whether these mutations are
also expressed in myocardium. We now describe a family with
FHC and a novel MyBP-C splice donor site mutation, in which
endomyocardial biopsy specimens of the index patient were
available for RNA and protein analysis.
 
Methods
 
Index family.
 
Since 1988, the clinical characteristics and blood sam-
ples of all patients with cardiomyopathy are collected in a registry at
the University Hospital of Heidelberg (Heidelberg, Germany). 51 pa-
tients were classified as having FHC. DNA from blood lymphocytes
of these patients was screened by single strand conformation poly-
morphism (SSCP) analysis for mutations in candidate genes including
cardiac MyBP-C. In one patient, a band shift in cardiac MyBP-C was
observed on SSCP. This index patient and his core family represent
the study group.
A detailed history was obtained by interviewing the index patient
and his sons. Members of the family who live in Turkey were not
available for clinical investigation. All members of the core family un-
derwent a physical examination, clinical chemistry testing, a 12-lead
electrocardiogram recording, and an echocardiographic study. The
diagnostic criteria for hypertrophic cardiomyopathy were defined as
unexplained hypertrophy of left ventricular myocardium, which was
assessed by M-mode echocardiographic measurements using the di-
agnostic criteria of the American Society of Echocardiography (11–
13). Left and right heart catheterization and coronary angiography
were performed in the index patient at baseline and at a 1-yr follow
up. Left ventricular wall thickness was assessed in 30
 
8
 
 left anterior ob-
lique projection by simultaneous injection of 30 ml contrast material
in both ventricular chambers. Six ventricular biopsies were taken from
the interventricular septum at baseline and at the 1-yr follow up. The
study protocol was approved by the ethics committee on human re-
search of the University of Heidelberg, and all participants gave in-
formed consent after a thorough explanation of the study protocol.
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Genotype analysis.
 
Microsatellite markers derived from the ge-
netic map of Gyapay et al. (14) were analyzed using the PCR condi-
tions and multiplex procedure described by Vignal (15). PCR products
were resolved according to size by polyacrylamide gel electrophoresis
as described below and detected by silver staining.
 
Linkage analysis.
 
Calculations of possible linkage by the com-
puter program MLINK (16) were performed with affection status as
indicated in Fig. 1 (below) and disease penetrance of 90%. Linkage
was tested for 
 
b
 
-myosin (MYO I, MYO II), 
 
a
 
-tropomyosin (D15S108,
D15S114), cardiac troponin T (D1S202, D1S412), and cardiac MyBP-C
genes (D11S1344, D11S1350, novel splice donor site mutation). The
allele frequency for the G
 
fi
 
A transversion in the cardiac MyBP-C
gene was estimated at 0.02 based on its absence from 250 normal
chromosomes (upper limit of the 95% binomial confidence interval
of 0/250).
 
DNA and RNA isolation from peripheral blood lymphocytes.
 
Genomic DNA was extracted from blood samples of all family mem-
bers using the genomic DNA extraction kit (Qiagen, Hilden, Germany)
in accordance with manufacturer’s protocol.
mRNA was extracted from peripheral lymphocytes, isolated from
whole blood over a Ficoll-Paque Plus (Pharmacia LKB Biotechnol-
ogy, Uppsala, Sweden) gradient with the Oligotex
 
™
 
 Direct mRNA
MidiKit (Qiagen).
 
RNA extraction from myocardial biopsies.
 
Total RNA was iso-
lated from endomyocardial biopsies of left ventricular myocardium ac-
cording to the method described by Chirgwin et al. (17).
 
Cardiac MyBP-C oligonucleotides.
 
All nucleotides were 20mers
synthesized according to the published cDNA sequence (18) and
numbered according to the position of the 5
 
9
 
 residue. F indicates for-
ward and R reverse orientation.
 
Amplification of cDNA sequences.
 
0.2 
 
m
 
g RNA obtained from
lymphocytes or myocardial tissue was reverse transcribed in a 20-
 
m
 
l
volume as follows; 4 
 
m
 
l of reverse transcription buffer, 2 
 
m
 
l of 0.1 M
DTT, 0.25 
 
m
 
l of RNA Guard, and 10 U H-Reverse Transcriptase Su-
perscript from GIBCO BRL, Life Technologies (Eggenstein, Ger-
many), 1 
 
m
 
l of 10 
 
m
 
M pd(N
 
6
 
)-primer, and 1 
 
m
 
l of 1 mM dNTP from
Pharmacia LKB Biotechnology were added to preheated (68
 
8
 
C, 5
min) RNA in a total volume of 20 
 
m
 
l. The reaction was incubated at
37
 
8
 
C for 1 h and terminated by heat inactivation (95
 
8
 
C, 5 min).
The cDNA products were then amplified in a 50-
 
m
 
l PCR reaction
using the outer primer pair 2968F and 3729R. The second round of
PCR was performed with a 1:100 final dilution of the first round prod-
ucts and the primer 3300F and the 5
 
9
 
-fluorescein–labeled primer
3566R (Pharmacia LKB Biotechnology). The amplification was per-
formed as follows: 0.5 
 
m
 
l of the reverse transcription product was
added to 50 
 
m
 
l of PCR mix. The PCR reaction mix contained 25 pM
of each primer, 200 
 
m
 
M 4-dNTP (Pharmacia LKB Biotechnology),
1 U Thermus aquaticus DNA polymerase (Pharmacia LKB Biotech-
nology), 10 mM Tris-HCL, pH 8.3, at room temperature, 50 mM KCl,
and 1.5 mM MgCl
 
2
 
. The PCR reaction was denatured by a 92.5
 
8
 
C in-
cubation for 3 min, and then amplified for 20, 25, 30, 35, 40, and 45 cy-
cles in a Hybaid Omnigene Temperature Cycler (Hybaid Ltd., Ted-
dington, UK). Each cycle consisted of denaturing at 92.5
 
8
 
C for 50 s,
annealing at 55
 
8
 
C for 50 s, and extension at 72
 
8
 
C for 60 s.
 
Semiquantitation of cDNA products.
 
PCR products were loaded
onto 5–15% polyacrylamide gradient gels (2,350 
 
3
 
 1,500 mm). The
products were separated on a Multiphor II Electrophoresis System
(Pharmacia LKB Biotechnology) by 60 mA for 2 h at 20
 
8
 
C and trans-
ferred to a nylon membrane (Biodyne A Transfer Membrane; Bio-
Support Division Pall Filtrationstechnik, Dreieich, Germany) essentially
as described (19). PCR products were visualized with the ECL-sys-
tem following the instructions of the supplier (Amersham Life
Sciences, Braunschweig, Germany). Blots were exposed on hyper-
film-MP (American Life Sciences) between 20 s and 5 min. The ratio
of the mutant to the wild-type allele was determined by densitometri-
cal scanning of the films (20).
 
Genomic DNA amplification.
 
The primer pairs 3300F–3490R
and 3445F–3576R were used to amplify the region of interest. The
PCR reaction mix contained 75 ng DNA as the template, 25 pM of
each primer, 200 
 
m
 
M 4-dNTP, 1 U Thermus aquaticus DNA poly-
merase, 10 mM Tris-HCL, pH 8.3, at room temperature, 50 mM
KCL, and 1.5 mM MgCl
 
2
 
 in a volume of 50 
 
m
 
l. The DNA was dena-
tured by exposing it to 92.5
 
8
 
C for 3 min, and then amplified for 30 cy-
cles in a Hybaid Omnigene Temperature Cycler. Each cycle consisted
of a denaturation step at 92.5
 
8
 
C for 50 s, an annealing step at 60
 
8
 
C for
50 s, and an extension step at 72
 
8
 
C for 60 s.
 
Single strand conformation polymorphism analysis.
 
 PCR prod-
ucts were denatured by adding 7 
 
m
 
l of 95% formamide to 7 
 
m
 
l of the
PCR product followed by heating for 5 min at 92.5
 
8
 
C. The solution
was then chilled on ice for 10 min, loaded onto 5–15% polyacryl-
amide gradient gels (2,350 
 
3
 
 1,500 mm). The products were sepa-
rated on a Multiphor II Electrophoresis System by 60 mA for 2 h at
20
 
8
 
C and visualized by silver staining (21).
 
BstnI endonuclease digest.
 
12 
 
m
 
l of the PCR product was digested
for 3 h at 60
 
8
 
C by 2 U of the restriction enzyme BstnI (New England
Biolabs Inc., Beverly, MA) in 25 
 
m
 
l with addition of the appropriate
buffer and 0.1 
 
m
 
g BSA. Fragments were resolved by electrophoresis
on 5–15% polyacrylamide gels as outlined above and visualized by
silver staining.
 
Cloning of PCR products.
 
DNA and cDNA sequences were con-
firmed by subcloning in a pBluescript II KS (
 
1
 
/
 
2
 
) phagemid vector
(Stratagene Inc., Heidelberg, Germany). Recombinant plasmid DNA
was purified by the alkaline lysis method (Plasmid DNA Extraction
Kit; Qiagen) and sequenced as described below.
The 241-bp genomic DNA fragment from the affected individual
contained amplified products from the normal and mutant alleles.
Therefore, a plasmid library was constructed and clones containing
the normal and the mutant PCR products were identified by BstnI di-
gestion.
 
Sequencing of PCR products.
 
For sequencing, amplified PCR prod-
ucts were gel-isolated with QiaxII Gel Extraction Kit (Qiagen). PCR-
amplified cDNA, genomic DNA fragments, and plasmid DNA were
sequenced on an ABI 373 DNA sequencing system (Perkin-Elmer
Corp., Applied Biosystems, Weiterstadt, Germany), using the ABI
PRISM Dye Terminatior Cycle Sequencing Kit with Amplitaq DNA
Polymerase, FS (Perkin-Elmer Corp., Foster City, CA). 20–40 ng of
PCR fragment purified by electrophoresis on agarose gels (10 ng/100-
bp fragment length, for sequencing of plasmid DNA 400 ng/reaction),
and 3.2 pmol of primer were used in a total volume of 20 
 
m
 
l. The se-
quencing reactions were performed on a GeneAMP PCR system
2400 (Perkin-Elmer Corp., Applied Biosystems). Cycling parameters
were as follows: preheating to 96
 
8
 
C, and then 25 cycles of 30 s at
96
 
8
 
C, 15 s at 50
 
8
 
C, and 4 min at 60
 
8
 
C each. Before loading onto the
gel, excess terminators were removed by ethanol precipitation. The
reactions were run on a 5.5% polyacrylamide gel (2,550 
 
3
 
 4,000 mm,
3,600 mm WTR) at 32 watts for 11 h.
 
Protein analysis.
 
Myocardial biopsies were transferred from 
 
2
 
80
 
8
 
C
directly to SDS-sample buffer with 6 M urea (22), preheated at 90
 
8
 
C,
and homogenized. Insoluble material was precipitated and the super-
natant analyzed on 14% SDS-polyacrylamide gels (22). For quantita-
tion, gels were stained with Coomassie brilliant blue and the actin
band quantified densitometrically with a gel scanner. Samples were
adjusted according to equal protein concentrations by appropriate di-
lution in SDS-sample buffer. Equal volumes were then separated on
8–12% gradient gels and transferred to nitrocellulose membranes
(BA85; Schleicher and Schüll, Dassel, Germany) by electroblotting
essentially as described (23). Cardiac MyBP-C was detected using the
rat polyclonal antibody I1 (18) and a novel rabbit antibody, R76, di-
rected against the recombinant NH
 
2
 
-terminal modules C1-C2 (I1) or
C0-C1 (R76) of human cardiac MyBP-C. Bound antibody was visual-
ized with anti–rat or rabbit horseradish peroxidase conjugate (Sigma
Chemical Co., Deisenhofen, Germany) and the ECL-system follow-
ing the instructions of the supplier (Amersham Life Science). Blots
were exposed on X-AR5 film (Eastman Kodak Co., Rochester, NY)
between 30 s and 20 min.
For generation of rabbit antiserum R76, the recombinant frag-
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ment C0-C1 was injected in a standardized scheme using TiterMax
adjuvant (CytR Corp., Norcoss, GA). Cardiac-specific reactivity was
assayed in immunofluorescence on cardiac and skeletal muscle cryo-
sections and by Western blotting as described (18).
To determine the detection limit of our Western blot, dilution se-
ries of the normal heart control were prepared in sample buffer and
blotted on 8% gels as described above. The dilution at which the
MyBP-C band was still discernible after 2.5-min exposure was de-
fined as the lower detection limit. To prove for incomplete extraction
of mutant MyBP-C, precipitated material was assayed after sample
buffer extraction by dot blotting in comparison with myofibrils ex-
tract.
 
Results
 
Clinical evaluation.
 
The clinical investigation of this Cauca-
sian family revealed classical features of FHC (Fig. 1). Three
family members had died suddenly at the age of 55, 61, and 50
yr (I-1, I-4, II-1). Individual II-5, the index patient, displayed
an interventricular septum thickness of 24 mm on biventricular
angiogram (Fig. 2) and echocardiogram. The histopathological
examination of his myocardial biopsies showed changes com-
patible with FHC such as myocyte hypertrophy and disarray.
Offspring III-4, III-6, III-7 had an interventricular septum
thickness over the 95% prediction limits according to echocar-
diographic normal values related to age and body surface area
(11–13). Individual III-3 was considered affected on a border-
line septal wall thickness of 11 mm, clinical symptoms and non-
specific ST-segment, and T-wave changes. All other members
of the family had normal clinical findings.
 
Genetic analysis.
 
Linkage analysis in this family with poly-
morphic markers excluded cosegregation of FHC with the
 
b
 
-myosin (MYO I, MYO II), 
 
a
 
-tropomyosin (D15S108,
D15S114), and cardiac troponin T (D1S202, D1S412) genes.
Linkage to cardiac MyBP-C gene on chromosome 11 was
tested using flanking markers D11S1344 and D11S1350, which
are located in the vicinity of cardiac MyBP-C (8). Both mark-
ers showed no recombination in the affected individuals avail-
able for genotyping. A maximum two-point logarithm of the
odds (LOD) score of 1.25 at 
 
u 5
 
 0 was achieved between FHC
and D11S1344, and 1.22 at 
 
u
 
 
 
5
 
 0 between FHC and the marker
D11S1350. A LOD score of 1.94 at 
 
u
 
 
 
5
 
 0 was calculated be-
tween FHC and the splice donor site mutation in the MyBP-C
gene.
 
RNA and DNA analysis.
 
Lymphocyte mRNA from affected
members was amplified by reverse transcription and nested
PCR (24–26). Amplification of cardiac MyBP-C cDNA with
primers 3300F and 3566R from affected individuals yielded
two distinct products: the expected 267-bp product and a 160-
bp shorter fragment (Fig. 3). Subcloning and sequencing of the
shorter cDNA fragment after gel extraction confirmed the de-
letion of the 160-bp stretch.
Genomic DNA was amplified with the primer pairs 3300F-
3490R and 3445F-3576R to determine whether the aberrant
cDNA resulted from a deletion of abnormal splicing. Fig. 4 
 
A
 
reveals different SSCP patterns between the affected and
healthy individuals when using the primers 3445F and 3576R,
but not when genomic primers 3300F and 3490R were used.
Since neither the structure nor the intronic sequences of
the cardiac MyBP-C gene were known, we determined the
exon–intron boundaries in the region spanning nucleotide po-
sitions 3300–3576 by direct sequencing of the genomic PCR
product. A 160-bp exon (residues 3363–3522) was identified
(Fig. 5). Both a normal intron sequence and a G
 
fi
 
A transition
were identified in the affected individual at position 1 of the 5
 
9
 
splice donor sequence gtgct (gtgct
 
fi
 
atgct). The G
 
fi
 
A transi-
Figure 1. Pedigree of family AY. 
Symbols denote sex and disease sta-
tus: box, male; circle, female; dark-
ened, affected; clear, unaffected; 
slashed, deceased. Genetic affec-
tion status is indicated: 1, mutation 
present; 2, mutation absent. Indi-
viduals identified with 1/2 were ge-
netically studied.
Figure 2. Biventricular angiogram of the index patient. Left ventricu-
lar wall thickness was assessed in 308 left anterior oblique projection 
by simultaneous injection of 30 ml contrast material in both ventricu-
lar chambers. LV, left ventricle; RV, right ventricle.
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tion abolishes a BstnI restriction site, allowing independent
confirmation of the mutation either by restriction enzyme di-
gestion or SSCP analysis. BstnI digestion of the 241-bp prod-
uct between 3445F and 3576R from unaffected individuals
showed four fragments of 117, 75, 27, and 22 bp. In contrast,
BstnI digestion of the 241-bp product from the index patient
and the affected individuals showed an additional fragment of
102 bp (Fig. 4, 
 
B
 
 and 
 
C
 
). This indicates the presence of both a
normal and mutant allele in affected family members. All clin-
ically affected members including the equivocal patient III-3 car-
ried the mutation. The mutation was present in neither the un-
affected family members nor 250 unrelated healthy individuals.
mRNA from two different left ventricular endomyocardial
biopsies of the index patient (II-5) was reverse transcribed and
amplified using primers 3300F and 3566R. Two cDNA prod-
ucts of 267 and 107 nucleotides were found confirming the re-
sults obtained from lymphocyte cDNA (Fig. 3). The shorter
cDNA fragment also lacked the exonic region between resi-
dues 3363 and 3522.
The ratio of the abnormally spliced, shorter cDNA frag-
ment to the wild-type cDNA fragment was determined by film
densitometry scanning (20). The signal of lymphocyte and my-
ocardial cDNA amplified from the mutant allele ranged from
85–95% of that observed from the wild-type allele depending
on the number of PCR cycles and the exposure time of the blot
to the film.
 
Protein analysis.
 
Western blot analysis for cardiac MyBP-C
of four individual biopsies from the index patient was per-
formed and the results compared with reference samples of
ventricular tissue from patients with aortic stenosis, ischemic
cardiomyopathy, and ventricular septum defect. The Western
blot with an antibody directed against the amino-terminal re-
gion of cardiac MyBP-C revealed the presence of a single band
corresponding to the normal protein in all samples investi-
gated (Fig. 6). In particular, the predicted truncated protein of
124.5 kD derived from translation of the misspliced mRNA of
the disease-associated allele could not be detected. Longer ex-
posures of the blot also did not reveal the predicted truncated
protein product. To address the possibility that antibody
epitopes could be masked in Western blot assay despite the
use of denaturing gels and blotting conditions, we assayed bi-
opsies 2 and 3 of the index patient in duplicate with a novel se-
rum (R76), raised against the recombinant fragment C0-C1 of
human cardiac MyBP-C. This serum reacted to the same band
Figure 3. Detection of 
cardiac MyBP-C splice 
donor site mutation. 
Cardiac MyBP-C 
cDNA amplified from 
lymphocyte (L) and 
myocardial (C) RNA 
from affected (A) and 
unaffected (U) family 
members using primers 
3300F and 3566R. Sam-
ples from affected indi-
viduals contained the 
normal 267-bp product 
and also a 107-bp prod-
uct resulting from skip-
ping of the 160-bp exon.
Figure 4. Identification of the point mutation in the cardiac MyBP-C 
gene. Symbols as in Fig. 1. (A) SSCP analysis of genomic PCR frag-
ments generated with 3445F and 3576R primers. Additional band (ar-
row) was observed in affected individuals. (B) BstnI enzyme diges-
tion of genomic PCR fragments generated with 3445F and 3576R 
primers. In the mutant allele, the loss of a BstnI restriction site results 
in noncleavage of a 102-bp fragment between nucleotide 3445 and 
the 25th nucleotide of the following intron. Short fragments (27 and 
22 bp) are hardly visible on the gel due to their small size. (C) BstnI 
restriction map of PCR fragment generated with 3445F and 3576R. 
BstnI restriction sites are indicated with arrows and nucleotides are 
numbered according to the Genbank/EMBL/DDBJ data library (ac-
cession No. X84075). The BstnI site, abolished by the splice donor 
site mutation, is marked with a dash.
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in the normal control as the serum I1. In the biopsy specimens,
we observed no discernible difference in the band patterns be-
tween the sera I1 and R76 (Fig. 7 
 
A
 
). Since incomplete extrac-
tion of mutant MyBP-C could also explain the lack of immu-
noreactive material in Western blots, we assayed the residual
material after sample buffer extraction by dot blotting in com-
parison with the total myofibrils extract. Residual material af-
ter extraction in sample buffer showed no immunoreactivity
with the anti–MyBP-C antibodies I1 and R76 (Fig. 7 D). We
conclude that MyBP-C can be readily extracted from myocar-
dial tissue using denaturing SDS/urea sample buffer.
The lower detection limit of the Western blot was defined
as the dilution at which the MyBP-C band was still discernible.
With exposure times of 2.5 min, this limit was 1.5% of the un-
diluted control (Fig. 7 C). We assume, therefore, that mutant
protein expressed at levels lower than 1.5% of wild type would
not be detectable in our assay. To investigate if lower amounts
of wild-type cardiac MyBP-C are expressed in diseased myo-
cardium, the amount of wild-type cardiac MyBP-C in patient
II-4 was measured by scanning and normalized to actin (Fig.
7 B). The amount of expressed protein appeared normal when
compared with unrelated control patients. Therefore, no evi-
dence for a lower expression due to a gene dose effect was
found.
Discussion
Recent findings defined cardiac MyBP-C mutations as a possi-
ble cause of FHC. Based on altered lymphocyte cDNA se-
quence, the mutations described so far are predicted to pro-
duce a truncated cardiac MyBP-C with disruption of the titin
and myosin-binding COOH-terminal region (27). Bonne et al.
(8) found a splice acceptor mutation of the MyBP-C gene in
two unrelated French families, which causes the skipping of
the associated exon and could eventually produce truncated
cardiac MyBP-C. The mutation described is located in the
linker module between immunoglobulin domains C4 and C5
(Fig. 8). Watkins et al. (9) demonstrated a splice donor muta-
tion in the immunoglobulin domain C9 and a duplication mu-
tation in immunoglobulin C10 domain in two families with
FHC. Both mutations are predicted to alter the myosin- and
titin-binding COOH terminus of cardiac MyBP-C. More re-
cently, six novel mutations in unrelated French families have
been identified, all of which were predicted to lead to expres-
sion of truncated cardiac MyBP-C (28). However, the tran-
scription of the mutant alleles in cardiac tissue and the fate of
the predicted truncated proteins remained unclear.
In this study, we have identified a novel mutation in the
cardiac MyBP-C gene from a Turkish family with FHC. The
splice donor site mutation in the COOH terminus (immuno-
globulin domain C9) was not observed in unaffected family
members and controls. The mutation cosegregates with the
disease in an autosomal dominant trait. Four endomyocardial
biopsies of the index patient were available and analyzed for
cardiac MyBP-C mRNA and protein composition. Study of
myocardial mRNA revealed two alleles: the normal and a mu-
tated allele with skipping of the associated exon. These find-
ings demonstrate that the mutation is transcribed to mRNA in
cardiac tissue. The skipping of exon N (Fig. 5) in cardiac
cDNA is a consequence of the Gfi A transition of the highly
conserved position 1 of the 59 splice donor consensus sequence
in the absence of an alternative splice donor site in the follow-
ing intron (29–31). Skipping of the 160-bp exon N produces a
frame shift. The aberrant cDNA encodes for a MyBP-C with
1,025 normal and 24 novel amino acids, followed by a prema-
ture termination of translation due to a TAG stop codon. As a
consequence, 164 amino acids of the conserved COOH termi-
nus are deleted (Fig. 8) and partially replaced by 24 novel resi-
dues, resulting in a mass difference of 16.4 kD. This mass dif-
ference is predicted to result in a detectable mobility shift on
protein gels. However, Western blot analysis with two differ-
ent antibodies failed to detect either the truncated protein or a
discernible reduction of nontruncated MyBP-C protein con-
centration compared with sarcomeric actin (Figs. 6 and 7 A).
The wild type allele of MyBP-C seems to largely compensate
Figure 5. The cardiac MyBP-C 
gene structure in the region of exon 
N. Nucleotide residues defining 
exon–intron boundaries are num-
bered below; exons are labeled ac-
cording to Watkins et al. (9). The 
gfi a transversion at position 1 of 
the 59 splice donor sequence (under-
lined) is indicated. The mutation 
abolishes a BstnI restriction site.
Figure 6. Western blot analyses of myocardial biopsies. Cardiac 
MyBP-C was detected using the rat polyclonal antibody I1 directed 
against the recombinant NH2-terminal modules C1-C2 of human car-
diac MyBP-C. Bound antibody was visualized with anti–rat-HRP 
conjugate and the ECL system. (Lanes 1–4) Different myocardial bi-
opsies from the index patient. (Lanes 5–7) Reference samples of ven-
tricular tissue from patients with ischemic cardiomyopathy (lane 5), 
aortic stenosis (lane 6), and ventricular septum defect (lane 7). C, car-
diac MyBP-C.
480 Rottbauer et al.
for the synthesis of MyBP-C protein in the assembled myo-
fibril.
Nondetection of the mutant MyBP-C due to altered folding
of the truncated peptide, and therefore altered exposure of the
relevant epitopes in both the regions C0-C1 and C1-C2, seems
to be unlikely in denaturing gels. Gilbert et al. (32) transfected
skeletal muscle myoblast with expression plasmids encoding
truncation mutants of MyBP-C. The truncation mutant Delta
D9-10, which is very similar to that produced by the splice donor
site mutation described here, could be detected with antibod-
ies directed against the NH2 terminus of the construct. The trun-
cation mutants of MyBP-C also migrated on SDS-PAGE with
the predicted mobility (32). Our Western blot assay showed
to be sensitive for small amounts of protein and could detect
z 1.5% of protein compared with wild-type MyBP-C (Fig. 7
C). We cannot, therefore, completely exclude the presence of
traces of truncated MyBP-C in myocardial tissue, which might
still act as a poison polypeptide. However, even long expo-
sures of the blots did not reveal a band of lower mobility than
the wild-type protein, specific for the diseased myocardium
(not shown). If truncated cardiac MyBP-C is present at all in
the myocardium, its levels are very low. A transgenic mouse
model for FHC with cardiac-specific expression of mutant rat
alpha myosin heavy chain demonstrated that already low lev-
els of mutant protein, 0.6–12% of the total myosin, in the pres-
ence of a normal actin/myosin stoichiometry induces a severe
phenotype of FHC. The authors suggested that the severe phe-
notype is due to the dominant effect of the mutant such that a
relatively small number of mutant polypeptides exert a “drag”
on sarcomere function (33). However, although the poison
peptide hypothesis cannot be totally excluded, as traces of mu-
tant MyBP-C could remain undetected, it is not the necessary
and sufficient mechanism for the genesis of FHC by mutations
in the cardiac MyBP-C. We propose that the changes of this
cardiac MyBP-C mutation must be sought in the assembly of
the sarcomere itself rather than in the assembled structure.
The absence of detectable amounts of truncated MyBP-C
protein despite the presence of the corresponding mRNA
transcript is plausibly explained by rapid proteolysis of the
nonassembled mutant protein by the proteasome complex of
developing muscle (34). The predicted result would be a dras-
tic change of protein stoichiometry during myofibril assembly.
Similarly, a rapid degradation of nonassembled, cytosolic
troponin T protein was described in a 59 splice donor site mu-
tation in intron 7 of Drosophila flight muscle troponin T, re-
sulting in the upheld2 phenotype (35). For mutations in the ac-
tin and myosin heavy chain genes of D. melanogaster, changes
in myofibrillar stoichiometry have been observed to result in
altered myofibril turnover and ultimately in myofibril disarray
(36). Since cardiac MyBP-C is essential for myofibrillar assem-
bly (27, 37), reduced amounts of functional protein during the
assembly process could equally lead to misassembly and sarco-
meric disarray, which is the histological hallmark of FHC.
Figure 7. Western blot analysis of myocardial biopsies. (A) Western 
blot analysis of control myocardium (lanes 1 and 4), and biopsies 2 
(lanes 2 and 5) and 3 (lanes 3 and 6) using two different polyclonal 
antibodies against different regions of the cardiac MyBP-C NH2 ter-
minus. Lanes 1–3, serum I1 (anti–C1-C2); lanes 4–6, serum R76 (anti–
C0-C1). The blots were loaded at twice the protein load as in Fig. 6 
and exposed for up to 6 min. Both antibodies detect the full-length 
MyBP-C, but no discernible additional bands specific for the biopsy 
specimens, even at the long exposure times and high protein loading 
used. (B) Control showing the actin band (arrow) of a Coomassie-
stained gel with replica lanes of 1–3 in A. The biopsies (lanes 2 and 3) 
show comparable actin bands as the control sample. The MyBP-C sig-
nals of the Western blot appears equal compared with the sarcomeric 
actin bands. (C) Dilution series of the normal heart control, probed 
with antibody I1 for cardiac MyBP-C. Lane 1, loading as in A. The 
concentration was decreased in steps of twofold (lane 2, 1/2; lane 3,
1/4; lane 4, 1/8; lane 5, 1/16; lane 6, 1/32; lane 7, 1/64). Exposure time 
of the blot was 2.5 min. Protein amounts corresponding to at least 
1.5% of the normal control can be detected. (D) Dot blot of SDS ex-
tract of biopsy 2 (lane 1) and the extracted particulate material (lane 
2). Cardiac MyBP-C immunoreactive material was detected with an-
tibody I1; exposure time was 3 min. The SDS extract corresponds to 
twice the gel loading as in A; the residual material was homogenized 
in 8 M urea corresponding to the volume of the SDS extract (100 ml), 
and equal volumes were spotted. No immunoreactive material is de-
tectable in the residual pellet of connective tissue, suggesting that 
MyBP-C can be completely extracted from the biopsy material by 
SDS/6M urea sample buffer.
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Our study shows that the diseased allele contributes to ap-
proximately similar levels of message as the wild-type allele,
but does not lead to detectable amounts of the truncated pro-
tein. This observation leaves neither the null allele nor the poi-
son peptide hypothesis as the only necessary and sufficient
causes for the genesis of FHC by mutations in the cardiac
MyBP-C. Possibly, other novel mechanisms are relevant to the
development of FHC. In this context, it may be significant that
different classes of mutations are typical for genes that are
known genetic causes of FHC. For the human cardiac b myo-
sin heavy chain gene, point mutations that locate in the head
or head-rod region of the protein are typical (for review see
reference 38). The point mutations in the cardiac b myosin
heavy chain gene indeed appear to be sufficient for the initia-
tion of FHC as recently confirmed by gene targeting studies in
mice (39). In contrast with the human cardiac b myosin heavy
chain mutations, none of the identified cardiac MyBP-C muta-
tions (8, 9, 28, and this study) resembles a point mutation.
Instead, all 10 mutations are splice donor, splice acceptor, de-
letion, or insertion mutations. Thereby, all mutations are pre-
dicted to lead to an altered mRNA sequence. Possibly, no trun-
cated cardiac MyBP-C expression can be detected despite the
presence of mutant transcripts, because MyBP-C translation
requires a correctly folded RNA template (for review see ref-
erence 40). On the protein level, cardiac MyBP-C is known to
bind to titin at multiple and regular intervals (27, 41), which
contributes to the formation of highly ordered and stable thick
filaments (32). The translation and the assembly of titin and
MyBP-C into sarcomeres are possibly coregulated and inter-
dependent. This may involve colocalization of the respective
mRNAs to spatially coordinate the assembly (42). Possibly, a
mutant cardiac MyBP-C transcript might therefore interfere
with the formation of ordered sarcomeres already on the
mRNA level. Such a scenario could explain why, so far, all
known mutations in the cardiac MyBP-C gene significantly af-
fect the transcript sequence by splice donor, splice acceptor, or
duplication mutations, and therefore presumably its folded
structure.
Two previous studies have described the effects of COOH-
terminally truncated MyBP-C transfected into vertebrate myo-
cytes (32, 43). These experiments, especially the detailed study
by Gilbert et al. (32), highlighted the complex interactions in
the COOH terminus of MyBP-C involved in sarcomere assem-
bly. It was demonstrated that the COOH-terminal Ig domain
is essential for thick-filament targeting. Domains C8–C10 are
minimal requirements for A-band incorporation. The lack of
domains C10 and/or C9 causes myofibrillar disarray only in the
presence of domain C8, while these constructs are not incorpo-
rated into the A-band in detectable amounts. In contrast,
COOH-terminally truncated constructs shorter than domain
C8 were neither dominant negative nor localized to the A-band.
Additional protein interactions, localized in the region that
binds to titin in vitro (27, 32), appear to be crucial for correct
sarcomeric assembly. The observed myofibrillar disarray thus
seems to be caused by competition of truncated MyBP-C with
A-band components, most likely titin. However, the transfec-
tion studies in cell culture with forced overexpression of mu-
tated protein under control of strong viral promoters resulted
in the rapid disturbance of sarcomere assembly (32, 43), which
contrasts with the late manifestation of FHC in family mem-
bers carrying the mutation and with the rather slow progres-
sion of the disease in clinically affected patients. Furthermore,
the splice acceptor mutation of MyBP-C described by Bonne
et al. (8) is predicted to produce a truncated protein, which is
lacking the domains C5–C10. The transfection studies by Gil-
bert et al. (32) did not reveal any significant dominant negative
effect on myofibrillar assembly for the similar construct D7-10.
Therefore, cell culture models and transfection assays may not
reflect the assembly control of myofibrillar proteins in the dis-
eased myocardium and therefore the pathogenesis of chromo-
some-11–associated FHC.
In conclusion, the common denominator of all MyBP-C
mutant proteins known to date is the loss of their thick-fila-
ment targeting region in domains C8–C10 by a variety of dif-
ferent and unrelated mutation mechanisms, either in the cod-
ing exons themselves or acting on transcript processing. Our
results suggest that the truncated unassembled polypeptide is
rapidly degraded. We propose, therefore, that disturbance of
the dynamic process of myofibrillar assembly by altered pro-
tein stoichiometry may be the most plausible cause for the re-
sulting disarray. Clearly, a better understanding of the causal
mechanisms that translate the mutations of the MyBP-C to the
clinical phenotype will require further analysis of possible in-
teractions of both the mutated MyBP-C protein and the tran-
script in vitro and the evaluation of their long term conse-
quences in the afflicted myocardium in transgenic animals.
Figure 8. Normal and mutant cardiac MyBP-C polypeptides. (A) The 
normal cardiac MyBP-C is composed of eight immunoglobulin-I mo-
tifs, (Ig-I motif), three fibronectin type III (fn-III motif) repeats, and 
the cardiac isoform-specific phosphorylation site (MyBP-C motif). 
Amino acid residue numbers are according to the Genbank/EMBL/
DDBJ data library (accession No. X84075). The domains essential for 
incorporation of MyBP-C into A-bands are marked according to Gil-
bert et al. (38). (B) The predicted truncated protein product of the 
aberrantly spliced MyBP-C cDNA. Skipping of the 160-bp exon N re-
sults in loss of the terminal 164 amino acid residues, including the
myosin-binding C10 domain; a frameshift encodes 24 novel residues 
followed by premature termination.
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